Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
SK Bioscience Co. Ltd. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners. Despite the involvement of multiple examiners, the portfolio is concentrated within 1 distinct art unit, which may lead to more consistent application of legal standards across the pending matters.
Benjamin P Blumel is the busiest examiner for the company, currently handling 1 pending office action. With 2 pending office actions in total, the workload is split between the 2 distinct examiners. The focus on 1 distinct art unit suggests that while the examiners differ, the technological context remains unified. Practitioners should prepare for a consistent technical environment while addressing the individual preferences of Benjamin P Blumel and the other assigned examiner.
The presence of 2 distinct examiners in 1 distinct art unit indicates that the company's Biotechnology & Pharmaceuticals filings are being scrutinized by different individuals within the same department. This allows for a specialized but varied examination process. A practitioner can use the shared art unit as a baseline for technical arguments while tailoring the procedural approach to Benjamin P Blumel. Successfully managing these 2 pending office actions requires balancing these individual examiner styles.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576816 | METHOD FOR PRODUCING REASSORTANT REOVIRIDAE VIRUS, AND VECTOR LIBRARY FOR SAME | BLUMEL, BENJAMIN P | — |
| 18562030 | METHOD FOR PREPARING REASSORTANT ROTAVIRUS | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576816 | METHOD FOR PRODUCING REASSORTANT REOVIRIDAE VIRUS, AND VECTOR LIBRARY FOR SAME | BLUMEL, BENJAMIN P | — |
| 18562030 | METHOD FOR PREPARING REASSORTANT ROTAVIRUS | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576816 | METHOD FOR PRODUCING REASSORTANT REOVIRIDAE VIRUS, AND VECTOR LIBRARY FOR SAME | BLUMEL, BENJAMIN P | 1671 | §102§103§112 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18562030 | METHOD FOR PREPARING REASSORTANT ROTAVIRUS | SIFFORD, JEFFREY MARK | 1671 | §102§103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial